Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case.
J Clin Neurosci
; 86: 79-84, 2021 Apr.
Article
in En
| MEDLINE
| ID: mdl-33775351
ABSTRACT
Neurofibromatosis type 2 (NF2) is a rare, hereditary tumor syndrome, often requiring repeated surgeries for multiple lesions with significant cumulative morbidity. As such, non-operative management should be considered when possible for this patient population. The aim of this study is to provide a systematic review of the literature regarding this treatment strategy. A descriptive case of a patient in whom bevacizumab treatments enabled over 15 years of surgical postponement for a symptomatic spinal cord ependymoma is also provided. Evidence suggests that bevacizumab is a reasonable surgery-deferring option for cystic lesions, and it may be especially useful in NF2 patients to reduce cumulative morbidity.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Spinal Cord Neoplasms
/
Neurofibromatosis 2
/
Ependymoma
/
Bevacizumab
/
Conservative Treatment
/
Antineoplastic Agents, Immunological
Type of study:
Systematic_reviews
Limits:
Adult
/
Female
/
Humans
Language:
En
Year:
2021
Type:
Article